Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL411517 | 1.00 | CA2 (0.58) | CA2ALDH1A1NPSR1CYP3A4TSHR | |
| SCHEMBL898388 | 1.00 | CA2 (0.58) | CA2ALDH1A1NPSR1CYP3A4TSHR | |
| SCHEMBL15847150 | 0.89 | CA2 (0.58) | CA2ALDH1A1NPSR1CYP3A4MAPT | |
| SCHEMBL1081119 | 0.89 | CA2 (0.58) | CA2ALDH1A1NPSR1CYP3A4MAPT | |
| SCHEMBL6041975 | 0.89 | CA2 (0.49) | CA2ALDH1A1NPSR1CYP3A4TSHR | |
| SCHEMBL29979605 | 0.88 | CA2 (0.46) | CA2ALDH1A1NPSR1CYP3A4TSHR | |
| SCHEMBL879857 | 0.86 | CA2 (0.46) | CA2ALDH1A1NPSR1CYP3A4TSHR | |
| SCHEMBL4294384 | 0.86 | CA2 (0.46) | CA2ALDH1A1NPSR1CYP3A4TSHR | |
| SCHEMBL2724163 | 0.86 | CA2 (0.46) | CA2ALDH1A1NPSR1CYP3A4TSHR | |
| SCHEMBL3490631 | 0.86 | CA2 (0.46) | CA2ALDH1A1NPSR1CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 376 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146035-A1 | FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS | DONG-A ST CO., LTD. (KR) | 2026-05-28 | — | — | US | disclosed |
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2025-10-09 | — | — | US | disclosed |
| EP-4605395-A2 | FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS | Dong-A ST Co., Ltd. (KR) | 2025-08-27 | — | — | EP | disclosed |
| WO-2025080788-A1 | CCR4 INHIBITORS AND METHODS OF USE THEREOF | RAYTHERA, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| US-20250092062-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2025-03-20 | — | — | US | disclosed |
| EP-4511375-A1 | BICYCLIC COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| US-20250009685-A1 | HYDROXYPHENYL-ETHYNYL-PHENOL DERIVATIVES AS AR (ANDROGEN RECEPTOR) TRANSCRIPTIONAL ACTIVITY MODULATORS FOR USE IN THE TREATMENT OF I.A. PROSTATE CANCER | FUNDACIO INST DE RECERCA BIOMEDICA IRB BARCELONA (ES) | 2025-01-09 | — | — | US | disclosed |
| US-20240228509-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2024-07-11 | — | — | US | disclosed |
| EP-3988541-B1 | HETEROCYCLIC COMPOUNDS FOR CANCER IMAGING AND TREATMENT AND METHODS FOR THEIR USE | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2024-06-26 | — | — | EP | disclosed |
| WO-2024084448-A2 | FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS | DONG-A ST CO., LTD. (KR) | 2024-04-25 | — | — | WO | disclosed |
| US-4946787-A | DOUBLE COATED LIPOSOME COMPLEX MADE UP OF POLYANION AND A LIPID | SYNTEX (U.S.A.) INC. (US) | 1990-08-07 | — | — | US | disclosed |
| EP-0147847-B1 | OPTICALLY ACTIVE COMPOUNDS WITH ANTITUSSIVE AND CENTRAL SEDATIVE ACTIVITY, A PROCESS FOR THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME | DOMPE' FARMACEUTICI S.p.A. (IT) | 1990-03-07 | — | — | EP | disclosed |
| US-4806655-A | Process for the stereospecific synthesis of indole derivatives | SOCIETE ANONYME: SANOFI (FR) | 1989-02-21 | — | — | US | disclosed |
| US-4764515-A | REDUCED SIDE EFFECTS | DOMPE' FARMACEUTICI S.P.A. (IT) | 1988-08-16 | — | — | US | disclosed |
| EP-0276196-A1 | Substituted dioxolane derivatives | CIBA-GEIGY AG (CH) | 1988-07-27 | — | — | EP | disclosed |
| EP-0265388-A1 | Pyrrole derivatives, therapeutic compositions containing them and their use | CIBA-GEIGY AG (CH) | 1988-04-27 | — | — | EP | disclosed |
| EP-0116825-B1 | NEW ARYLOXYPROPANOLAMINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC USE | Pierrel S.p.A. (IT) | 1987-12-16 | — | — | EP | disclosed |
| US-4699911-A | Levo and dextro dropropizine having antitussive activity | DOMPE' FARMACEUTICI S.P.A. (IT) | 1987-10-13 | — | — | US | disclosed |
| US-4579861-A | Aryloxypropanolamine derivatives, pharmaceutical compositions and adrenegic thereof | PIERREL S.P.A. (IT) | 1986-04-01 | — | — | US | disclosed |
| EP-0147847-A2 | Optically active compounds with antitussive and central sedative activity, a process for the preparation thereof and compositions containing the same | DOMPE' FARMACEUTICI S.p.A. (IT) | 1985-07-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228509-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | CA2 4674/4885ALDH1A1 641/4885NPSR1 4573/4885 |
| US-20250092062-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | CA2 4674/4885ALDH1A1 641/4885NPSR1 4573/4885 |
| US-20250009685-A1 | HYDROXYPHENYL-ETHYNYL-PHENOL DERIVATIVES AS AR (ANDROGEN RECEPTOR) TRANSCRIPTIONAL ACTIVITY MODULATORS FOR USE IN THE TREATMENT OF I.A. PROSTATE CANCER | AR, NCOA1, NR5A1 | CA2 4290/4885ALDH1A1 303/4885NPSR1 1290/4885 |
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | CA2 4674/4885ALDH1A1 641/4885NPSR1 4573/4885 |
| US-20260146035-A1 | FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS | AXL, ERBB2, ERBB3 | CA2 476/4885ALDH1A1 2378/4885NPSR1 1431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.